The JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, published by Walter de Gruyter GmbH, is a reputable peer-reviewed journal dedicated to advancing the field of pediatric endocrinology and metabolism. Since its inception in 1985, this journal has become a vital resource for professionals and researchers, providing insights into the latest advancements, clinical practices, and foundational research in the care of children with endocrine disorders. With a noted Q3 ranking in Endocrinology, Diabetes and Metabolism, and a robust focus on Pediatrics, Perinatology, and Child Health, it addresses important topics such as hormonal imbalances and metabolic syndromes in young populations. Despite its non-open access status, it continues to play an essential role in bridging the knowledge gap within our understanding of children's health and disease, contributing significantly to the progress in this specialized field.

Molecular Metabolism is a premier, open-access journal published by Elsevier, dedicated to advancing the understanding of metabolic processes at the molecular level. With an ISSN of 2212-8778 and a proud presence in Germany, the journal has made significant contributions to the fields of Cell Biology and Molecular Biology, consistently achieving a Q1 ranking in both categories as of 2023. The journal’s scope encompasses cutting-edge research that explores metabolic pathways, their regulation, and implications for human health, underscoring the interplay between metabolism and various biological functions. Researchers and professionals benefit from the journal’s robust visibility, as it ranks #40 among 410 journals in Molecular Biology and #35 among 285 in Cell Biology according to Scopus metrics, placing it in the top 10 percentile in its field. With open access since 2012, Molecular Metabolism ensures that groundbreaking research is available to all, fostering a collaborative and inclusive academic environment. Its commitment to excellence and accessibility makes it an invaluable resource for those invested in metabolic research.

Expert Review of Endocrinology & Metabolism is a premier journal dedicated to advancing the field of endocrinology and metabolism, published by Routledge Journals, Taylor & Francis Ltd, in the United Kingdom. With a robust focus on the latest research, innovative treatments, and clinical practices, this journal serves as an essential resource for healthcare professionals, researchers, and students seeking to stay abreast of developments in diabetes, obesity, thyroid disorders, and other endocrine-related conditions. Achieving a commendable Q2 status in Endocrinology, Diabetes, and Metabolism in the 2023 ranking, Expert Review of Endocrinology & Metabolism holds strong standing with an impressive Scopus rank, placing it at the 53rd percentile among its peers. The journal embraces a comprehensive approach, offering critical reviews, original research articles, and insights on emerging trends and technologies in the field. Although not an open-access journal, it provides extensive access options for subscribers and institutions, encouraging ease of dissemination and academic engagement. Through its commitment to high-quality content, Expert Review of Endocrinology & Metabolism remains pivotal for professionals aiming to enhance their understanding and practice in this vital area of medicine.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

American Journal of Physiology-Endocrinology and Metabolism, published by the American Physiological Society, stands as a leading platform for disseminating high-quality research in the fields of endocrinology, diabetes, and metabolism, as well as general physiology. With an impressive impact factor placing it within the Q1 category across multiple relevant disciplines (Endocrinology, Diabetes and Metabolism; Physiology; and Medical Physiology), this journal reflects its authoritative position in the scientific community. Spanning from 1980 to 2024, the journal consistently publishes groundbreaking studies and significant findings that advance our understanding of hormonal regulation and metabolic processes. Although it does not currently offer open access, it provides valuable resources for researchers, professionals, and students alike, eager to stay at the forefront of advancements in physiological sciences. Addressed in Rockville, Maryland, its commitment to excellence and rigorous peer review ensures that every article contributes essential insights to the field.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Frontiers in Endocrinology, published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to the advancement of research in the fields of endocrinology, diabetes, and metabolism. Established in 2010, this journal has consistently demonstrated its academic excellence, achieving a prominent Q1 quartile ranking in its category as of 2023, and a commendable Scopus rank of #96 out of 244, placing it within the 60th percentile. The journal is committed to disseminating high-quality research that encompasses a wide range of topics within endocrinology, catering to the needs of a diverse audience that includes researchers, medical professionals, and students alike. With the critical goal of fostering knowledge-sharing and collaboration within the scientific community, Frontiers in Endocrinology is an invaluable resource for anyone looking to stay updated on the latest advancements and insights in endocrinology. It operates under a robust open-access model, ensuring that groundbreaking research is accessible to all, thereby driving innovation and progress in this essential field.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, published by the Endocrine Society, stands as a premier academic journal within the field of endocrinology, diabetes, and metabolism. With a legacy spanning from 1941 to 2024, this journal is distinguished by its significant impact factor, ranking in the Q1 category across multiple related disciplines including biochemistry, clinical biochemistry, and medicine. This esteemed journal, ISSN 0021-972X and E-ISSN 1945-7197, is backed by rigorous peer review, ensuring the publication of high-quality research that contributes to the advancement of clinical practices and scientific knowledge. With a commendable Scopus ranking, positioned in the top percentile of multiple categories, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM serves as an essential resource for researchers, professionals, and students who seek to stay informed about the latest findings and innovations in endocrine research. The journal enriches the existing body of knowledge and fosters discussion among scholars and practitioners alike, solidifying its crucial role in the ongoing discourse in endocrinology and metabolic health.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM is a leading academic journal published by Elsevier that focuses on the dynamic field of endocrinology and metabolism. With an impressive impact factor reflected in its Q1 ranking in both endocrinology and endocrinology, diabetes, and metabolism for 2023, this journal is essential for researchers, healthcare professionals, and students seeking to stay abreast of the most significant developments in clinical practice and research. Covering a wide range of topics within the scope of endocrinology, the journal provides a platform for innovative research, comprehensive reviews, and insightful case studies, all aimed at enhancing patient care and advancing the field. With robust rankings, including a position of 22nd out of 244 in Endocrinology and a 90th percentile ranking in Biochemistry, Genetics, and Molecular Biology, this journal is recognized for its scholarly contribution and relevance. As an open-access journal, it ensures that valuable research is accessible to a global audience, advancing knowledge and clinical practice in endocrinology.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.